BioArctic: Interim Report for the period April - June 2025
Increasing Leqembi® royalties and new partnership with Novartis
STOCKHOLM, Aug. 28, 2025 /PRNewswire/ --
Events during the second quarter 2025
The European Commission granted Marketing Authorisation (MA) for Leqembi® (lecanemab), triggering a milestone payment of EUR 20 M from Eisai
The EU granted Exidavnemab orphan designation for multiple system atrophy (MSA) and the European Patent Office extended patent protection until 2041
Approval to include MSA patients in the phase 2a study with exidavnemab
BioArctic's partner Eisai issued Leqembi sales forecast of JPY 76.5 billion for its fiscal year 2025 (Apr-25, Mar-26), representing a 73% increase year over year
The safety review of the first part of the phase 2a study with exidavnemab supported initiating the second part of the study with a higher dose
BioArctic launched 2030 ambitions at Capital Markets Day
Events after the end of the second quarter
The latest findings on lecanemab were presented at the AAIC conference which:
showed that early and continued treatment with lecanemab indicated increasing benefit after four years with maintained safety profile
real world data from nine US clinics where 84% of patients did not progress to the next stage of the disease, with safety data in line with the Clarity AD study
confirmed appropriateness of 360 mg weekly subcutaneous dosing for maintenance treatment, and equivalency with current IV maintenance treatment
Leqembi launch initiated in the EU, starting in Austria and Germany
Option, collaboration and license agreement signed with Novartis, with an upfront payment of USD 30 million plus additional potential milestones and royalties
Financial summary April, June 2025
Net revenues amounted to SEK 392.1 M (49.8), of which SEK 162.5 M (42.6) in royalties for Leqembi
Operating profit amounted to SEK 179.1 M (-75.8)
Profit for the period amounted to SEK 96.6 M (-68.4)
Earnings per share before dilution amounted to SEK 1.09 (-0.77)
Earnings per share before and after dilution amounted to SEK 1.09 (-0.77)
Cash flow from operating activities amounted to SEK 1,147.1 M (-94.3)
Cash and cash equivalents and short-term investments at the end of the period amounted to SEK 1,916.1 M (889.7)
Comments from the CEO
"We are already starting to deliver on our newly launched ambitions for 2030."
It has been an eventful and very positive period since our last report. We have seen strong data for Leqembi, a clear increase in sales, continued progress in our development portfolio, and successfully held our first Capital Markets Day. After the end of the second quarter we also signed a new collaboration agreement with another of the world's largest pharmaceutical companies. We are already starting to deliver on our newly launched ambitions for 2030.
I am particularly excited about our new agreement with Novartis, announced this week. It differs from our previous collaborations as it combines our BrainTransporter™ technology with one of Novartis' own drug candidates. This is an important recognition of the growing need for precision neurology and of the unique potential of our BrainTransporter platform in particular. The ...
